
4 Largecap High ROE Quarterly Sales and Profit Growth Stocks to Watch for Future Multibagger Potential: Hindustan Zinc, Trent, Laurus Labs and Apollo Hospitals
Hindustan Zinc Rs 554.85. Trent Rs 3,165.20. Laurus Labs Rs 2,424. Apollo Hospitals Rs 8,526. Market caps from Rs 1.22 lakh crore to Rs 2.34 lakh crore. Data as of 13 Nov 2026.
Updated: 16 Nov 2026 • 10:53 am
Posted by:

Quick Answer
Hindustan Zinc, Trent, Laurus Labs and Apollo Hospitals are the 4 picks in this high ROE quarterly sales and profit growth stocks watchlist, with market caps between Rs 1.22 lakh crore and Rs 2.34 lakh crore. Hindustan Zinc stands out for the highest return on equity at 69.51%, while Hindustan Zinc offers the lowest PE of the group at 11.24. PE ratios run from 11.24 to 98.13, so compare each one with its industry PE before investing. All figures are as of 13 November 2026.
High ROE quarterly sales and profit growth stocks to watch for multibagger potential start with a simple filter: size, a clean financial record and earnings that keep growing. Hindustan Zinc, Trent, Laurus Labs and Apollo Hospitals meet that test, with market caps from Rs 1.22 lakh crore to Rs 2.34 lakh crore and Hindustan Zinc offering the highest return on equity at 69.51%. Each of these companies has a return on equity of at least 20 per cent, latest-quarter revenue growth of at least 15 per cent year on year, latest-quarter net profit growth of at least 20 per cent year on year, net profit growth in FY26 and in the latest quarter, and market capitalisation above Rs 1,00,000 crore.
This list covers companies with strong returns on equity and rising quarterly sales and profit, ranked by market capitalisation. Every company has complete, verifiable financials, and investors screening high ROE quarterly sales and profit growth stocks usually begin with size and balance sheet strength, so this list follows the same logic. All figures are as of 13 November 2026 and are drawn from NSE and BSE data and company filings.
Click Here – Get Free Investment Predictions
What Are High ROE Quarterly Sales and Profit Growth Stocks and Why Do They Attract Multibagger Interest?
High ROE quarterly sales and profit growth stocks are shares of companies that clear several growth and quality tests at once: a return on equity of at least 20 per cent, latest-quarter revenue growth of at least 15 per cent year on year and latest-quarter net profit growth of at least 20 per cent year on year. The 4 here cover fashion retail, hospitals and healthcare, pharmaceutical ingredients and zinc.
A multi-year growth record together with a strong latest year and a rising latest quarter shows that demand for the business is steady and not a one-off spike. Within high ROE quarterly sales and profit growth stocks, all 4 companies show rising profit in FY26 and in the latest quarter, which is the first check most investors make. With high ROE quarterly sales and profit growth stocks, comparing valuation, growth and balance sheet strength together works better than relying on one number. Anyone shortlisting high ROE quarterly sales and profit growth stocks should compare valuation, growth and balance sheet strength together rather than relying on one number. Read each company's latest results and exchange filings before acting on high ROE quarterly sales and profit growth stocks. The figures for high ROE quarterly sales and profit growth stocks in this article come from NSE and BSE data and company filings, and they are complete for every name shown. Within high ROE quarterly sales and profit growth stocks, the common thread is rising profit backed by complete financial data. Track every result season for high ROE quarterly sales and profit growth stocks, because earnings growth is what supports the share price over time.
High ROE Quarterly Sales and Profit Growth Stocks at a Glance: Price, Market Cap, PE and ROE
Prices are closing prices as of 13 November 2026. Hindustan Zinc has the lowest PE of the group at 11.24, while Hindustan Zinc posts the highest return on equity at 69.51%.
| Stock | CMP (Rs) | Market Cap (Rs Cr) | PE | Industry PE | ROE | Price to Book | Dividend Yield |
|---|---|---|---|---|---|---|---|
| Hindustan Zinc | 554.85 | 2,34,209 | 11.24 | 10.11 | 69.51% | 7.82 | 1.80% |
| Trent | 3,165.20 | 1,68,501 | 88.24 | 64.93 | 24.40% | 21.69 | 0.08% |
| Laurus Labs | 2,424 | 1,30,756 | 98.13 | 40.65 | 22.11% | 21.57 | 0.08% |
| Apollo Hospitals Enterprise | 8,526 | 1,22,440 | 52.38 | 62.49 | 21.14% | 11.55 | 0.23% |
Hindustan Zinc: September 2026 Quarter Profit Up 142.05%
Hindustan Zinc is among the world's largest integrated zinc producers and also produces lead and silver. It reported FY26 revenue of Rs 41,934 crore, up 19.59% year on year, and net profit of Rs 13,832 crore, up 33.60%. Net profit has compounded at 9.48% a year since FY22, while revenue has grown 8.15% a year. Operating margin was 56.75% in FY26. The debt-to-equity ratio is 0.22, which keeps interest costs low.
In the September 2026 quarter, revenue rose 76.02% to Rs 15,467 crore and net profit grew 142.05% to Rs 6,412 crore. Foreign investors raised their holding from 1.31% in September 2025 to 2.36% in September 2026. The stock trades at a PE of 11.24 against an industry PE of 10.11, with a return on equity of 69.51% and a price to book of 7.82.
Trent: September 2026 Quarter Profit Up 25.35%
Trent runs the Westside, Zudio and Star retail chains selling fashion, apparel and grocery products. It reported FY26 revenue of Rs 20,189.05 crore, up 16.34% year on year, and net profit of Rs 1,721.33 crore, up 12.18%. Net profit has compounded at 165.58% a year since FY22, while revenue has grown 44.17% a year. Operating margin was 17.91% in FY26.
In the September 2026 quarter, revenue rose 21.75% to Rs 5,899.25 crore and net profit grew 25.35% to Rs 468.09 crore. Domestic institutions raised their holding from 19.98% in September 2025 to 23.33% in September 2026. The stock trades at a PE of 88.24 against an industry PE of 64.93, with a return on equity of 24.40% and a price to book of 21.69.
Laurus Labs: September 2026 Quarter Profit Up 125.41%
Laurus Labs makes active pharmaceutical ingredients and formulations and offers contract development and manufacturing services. It reported FY26 revenue of Rs 6,867.85 crore, up 22.01% year on year, and net profit of Rs 889.85 crore, up 151.08%. Net profit has compounded at 1.68% a year since FY22, while revenue has grown 8.53% a year. Operating margin was 26.90% in FY26.
In the September 2026 quarter, revenue rose 32.07% to Rs 2,219.38 crore and net profit grew 125.41% to Rs 436.74 crore. Foreign investors raised their holding from 26.16% in September 2025 to 30.84% in September 2026. The stock trades at a PE of 98.13 against an industry PE of 40.65, with a return on equity of 22.11% and a price to book of 21.57.
Apollo Hospitals: September 2026 Quarter Profit Up 33.50%
Apollo Hospitals Enterprise runs one of India's largest hospital networks and also operates pharmacies and a digital health platform. It reported FY26 revenue of Rs 25,420.10 crore, up 15.58% year on year, and net profit of Rs 2,002.70 crore, up 33.06%. Net profit has compounded at 16.13% a year since FY22, while revenue has grown 14.59% a year. Operating margin was 15.80% in FY26.
In the September 2026 quarter, revenue rose 22.69% to Rs 7,659.70 crore and net profit grew 33.50% to Rs 659.50 crore. Domestic institutions raised their holding from 21.12% in September 2025 to 22.07% in September 2026. The stock trades at a PE of 52.38 against an industry PE of 62.49, below the sector average, with a return on equity of 21.14% and a price to book of 11.55.
High ROE Quarterly Sales and Profit Growth Stocks: Financial Comparison on Growth and Margins
The table compares scale and growth across these high ROE quarterly sales and profit growth stocks. Latest quarter means the most recent reported quarter for each company, and only metrics that are positive for every company are shown.
| Stock | Revenue (Rs Cr) | Net Profit (Rs Cr) | Revenue Growth (YoY) | 4-Year Revenue CAGR | 4-Year Net Profit CAGR | Latest Quarter Profit Growth (YoY) |
|---|---|---|---|---|---|---|
| Hindustan Zinc | 41,934 | 13,832 | 19.59% | 8.15% | 9.48% | 142.05% |
| Trent | 20,189.05 | 1,721.33 | 16.34% | 44.17% | 165.58% | 25.35% |
| Laurus Labs | 6,867.85 | 889.85 | 22.01% | 8.53% | 1.68% | 125.41% |
| Apollo Hospitals | 25,420.10 | 2,002.70 | 15.58% | 14.59% | 16.13% | 33.50% |
Check the Univest Screener for live data on these high ROE quarterly sales and profit growth stocks
Institutional Holding in Hindustan Zinc, Trent, Laurus Labs and Apollo Hospitals
Institutional holding shows who is backing these high ROE quarterly sales and profit growth stocks alongside the promoter. The table uses the latest reported quarter for each. Apollo Hospitals has the deepest institutional backing, with FII and DII together holding 65.25% as of September 2026. Domestic institutions increased their holding over the past year in Trent (from 19.98% to 23.33%) and Apollo Hospitals (from 21.12% to 22.07%). To see how this group fits the wider market, many investors compare it with the Nifty 50.
| Stock | Promoter | FII | DII | Public | Quarter |
|---|---|---|---|---|---|
| Hindustan Zinc | 60.71% | 2.36% | 4.85% | 32.07% | September 2026 |
| Trent | 37.01% | 15.28% | 23.33% | 24.39% | September 2026 |
| Laurus Labs | 27.47% | 30.84% | 11.86% | 29.83% | September 2026 |
| Apollo Hospitals | 28.02% | 43.18% | 22.07% | 6.72% | September 2026 |
Risks to Weigh in High ROE Quarterly Sales and Profit Growth Stocks
Being careful with high ROE quarterly sales and profit growth stocks means looking at what can slow the story as well as what can speed it up. Four points matter most:
- Past growth may not repeat.
- Share prices can move sharply in either direction.
- Valuation: Laurus Labs trades at a PE of 98.13 against an industry PE of 40.65, so earnings need to keep growing to support the price.
- Concentration: Holding all 4 names puts the allocation in one theme, so size each position to match your risk appetite.
How to Choose Between High ROE Quarterly Sales and Profit Growth Stocks
Picking from high ROE quarterly sales and profit growth stocks comes down to four checks, applied in order.
- Check balance sheet strength first, and prefer a debt-to-equity ratio below 1 for non-financial companies.
- Compare each PE with the industry PE (10.11 to 64.93) and ask whether the growth rate justifies any gap.
- Track net profit growth, the operating margin and the return on equity in every quarterly result.
- Stagger entries across quarters and review institutional holding every reporting season.
Download the Univest iOS App or Univest Android App to track Hindustan Zinc, Trent, Laurus Labs and Apollo Hospitals live prices.
Conclusion
Among high ROE quarterly sales and profit growth stocks, Hindustan Zinc stands out for the highest return on equity at 69.51%, Hindustan Zinc for the lowest PE of the group at 11.24, Trent for the fastest profit compounding at 165.58% a year since FY22 and Hindustan Zinc for the sharpest latest-quarter profit growth at 142.05%. Which one suits a portfolio depends on how much valuation risk it can carry, so staggering entries and reviewing each quarterly result is a sound habit. Investors comparing high ROE quarterly sales and profit growth stocks should rank them on growth, financial strength and the price paid, and anyone who wants personalised guidance can consult a SEBI-registered advisor before acting.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions on High ROE Quarterly Sales and Profit Growth Stocks to Watch
Which are the best high ROE quarterly sales and profit growth stocks to watch for multibagger potential?
Ans. Hindustan Zinc, Trent, Laurus Labs and Apollo Hospitals are the 4 names this list highlights, with market caps of Rs 2,34,209 crore, Rs 1,68,501 crore, Rs 1,30,756 crore and Rs 1,22,440 crore respectively. Hindustan Zinc is notable for the highest return on equity at 69.51%. Hindustan Zinc stands out for the lowest PE of the group at 11.24. Trent offers the fastest profit growth, 165.58% a year since FY22. Hindustan Zinc brings the sharpest latest-quarter profit growth at 142.05%. These are watchlist names for high ROE quarterly sales and profit growth stocks, not recommendations, so match each one to your own risk profile and time horizon.
Is Hindustan Zinc a good stock for long-term investors?
Ans. Hindustan Zinc has a return on equity of 69.51%, a PE of 11.24 against an industry PE of 10.11 and a market cap of Rs 2,34,209 crore. Net profit has compounded at 9.48% a year since FY22, and FY26 revenue rose 19.59% while September 2026 quarter net profit grew 142.05%. Long-term returns in high ROE quarterly sales and profit growth stocks depend on earnings growth and the price paid at entry, so staggering purchases and consulting a SEBI-registered advisor is sensible.
Can Trent become a multibagger from here?
Ans. A multibagger outcome in high ROE quarterly sales and profit growth stocks requires earnings to keep growing faster than the market for several years. Trent has grown revenue at 44.17% a year since FY22 and net profit at 165.58% a year, and FY26 revenue rose 16.34%. At a PE of 88.24 against an industry PE of 64.93, valuation should be checked against that growth before investing, and no outcome is guaranteed.
What is the market cap of Hindustan Zinc, Trent, Laurus Labs and Apollo Hospitals?
Ans. As of 13 November 2026, Hindustan Zinc has a market cap of Rs 2,34,209 crore, Trent has a market cap of Rs 1,68,501 crore, Laurus Labs has a market cap of Rs 1,30,756 crore and Apollo Hospitals has a market cap of Rs 1,22,440 crore. All of them qualify as largecaps. Market cap changes daily with the share price, so check the latest figure on the Univest Screener or on NSE before taking a decision on high ROE quarterly sales and profit growth stocks.
What are the risks of investing in high ROE quarterly sales and profit growth stocks?
Ans. The main risks are market swings, slower growth than expected and valuations that already reflect good news. Companies with strong balance sheets and steady earnings handle these better. Laurus Labs trades at a PE of 98.13 against an industry PE of 40.65, so earnings growth needs to hold up. Diversifying across the 4 names and reviewing each quarterly result helps keep risk in check.
Why is Laurus Labs trading at a PE of 98.13?
Ans. Laurus Labs's PE of 98.13 compares with an industry PE of 40.65. The market is paying a premium for a return on equity of 22.11%, profit growth of 1.68% a year since FY22 and latest-quarter profit growth of 125.41%, which also means the stock is more sensitive if growth slows. Investors in high ROE quarterly sales and profit growth stocks who are comfortable with higher valuation risk may prefer to stagger purchases instead of investing in one go.
How much do institutions hold in Hindustan Zinc, Trent, Laurus Labs and Apollo Hospitals?
Ans. As of the latest reported quarter, FII and DII together hold 7.21% of Hindustan Zinc (2.36% and 4.85%), 38.61% of Trent (15.28% and 23.33%), 42.70% of Laurus Labs (30.84% and 11.86%) and 65.25% of Apollo Hospitals (43.18% and 22.07%). Rising institutional holding is a useful signal in high ROE quarterly sales and profit growth stocks, though it should be read with earnings trends rather than on its own.
Recent Articles

4 Smallcap Price to Book Below 5 Quarterly Sales and Profit Growth Stocks to Watch for Future Multibagger Potential: Capri Global, GE Shipping, VA Tech Wabag and Shipping Corporation
16 November 2026

4 Smallcap PE Below 30 Quarterly Sales and Profit Growth Stocks to Watch for Future Multibagger Potential: Capri Global, GE Shipping, Emmvee and Time Technoplast
16 November 2026

4 Largecap PE Below 30 Quarterly Sales and Profit Growth Stocks to Watch for Future Multibagger Potential: L&T, M&M, Bajaj Finserv and Bajaj Auto
16 November 2026

4 Smallcap Promoter Backed Profit CAGR Quarterly Profit Growth Stocks to Watch for Future Multibagger Potential: Happy Forgings, Paras Defence, TRIL and PN Gadgil
16 November 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
4 Smallcap Price to Book Below 5 Quarterly Sales and Profit Growth Stocks to Watch for Future Multibagger Potential: Capri Global, GE Shipping, VA Tech Wabag and Shipping Corporation
4 Smallcap PE Below 30 Quarterly Sales and Profit Growth Stocks to Watch for Future Multibagger Potential: Capri Global, GE Shipping, Emmvee and Time Technoplast
4 Largecap PE Below 30 Quarterly Sales and Profit Growth Stocks to Watch for Future Multibagger Potential: L&T, M&M, Bajaj Finserv and Bajaj Auto
4 Smallcap Promoter Backed Profit CAGR Quarterly Profit Growth Stocks to Watch for Future Multibagger Potential: Happy Forgings, Paras Defence, TRIL and PN Gadgil
4 Midcap Promoter Backed Profit CAGR Quarterly Profit Growth Stocks to Watch for Future Multibagger Potential: Uno Minda, Apar Industries, NALCO and Endurance

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





